Tedizolid Prolonged Treatment for Prosthetic Joint Infections

• Status: Completed
• Trial end date: 2021-08-22
• Target enrollment: 0
• Participant gender: All

Summary

Pilot study the aim of which is to obtain reliable data on the tolerance, compliance and efficacy of Tedizolid used as prolonged (≥ 6 weeks) monotherapy or in combination therapy for the treatment of patients with orthopedic device infections due to Gram positive cocci.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tourcoing Hospital
• Collaborator: Eric SENNEVILLE M.D. Ph.D.
• Treatments: Ciprofloxacin; Clindamycin; Doxycycline; Fusidic Acid; Levofloxacin; Minocycline; Ofloxacin; Rifampin; Sulfamethoxazole; Tedizolid; Tedizolid phosphate; Teicoplanin; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination

Criteria

Inclusion Criteria:

• Patient at least 18 years;

• Orthopedic device infection defined according to the French recommendations published in 2009 (Med Mal Infect 2009; 39:745-774) for which TEDIZOLID treatment is proposed according to the investigator's decision;

• Bacterial documentation of the infection will only be based on the results of reliable samples such as joint aspiration and peroperative samples.

• Requiring TEDIZOLID administration as a single antibiotic therapy or in combination therapy including another agent with proven activity against the involved pathogen(s);

• No contraindication to TEDIZOLID;

• Provide a signed informed consent for the trial.

Exclusion Criteria:

• pregnant women or of childbearing age without contraception, breastfeeding,

• intolerance to TEDIZOLID;

• allergy to LINEZOLID;

• bactéria non susceptible to TEDIZOLID;

• patient with uncertainty regarding the possibility to achieve one-year follow-up after the end of treatment.